RILPL2

Across TCGA pan-cancer cohorts, RILPL2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of RILPL2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RILPL2 RNA is repressed in tumor relative to normal tissue. In most cancer types RILPL2 is over-expressed in tumor, although a few such as LUAD and KICH show the opposite, repressed pattern.

LUAD, KICH, and THCA are the cancer types where RILPL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RILPL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−1.658	<.001	11	view →
KICH	Male	All	−1.797	<.001	10	view →
THCA	Male	III,IV	−1.032	<.001	9	view →
LUSC	Female	All	−1.279	<.001	8	view →
COAD	All	II,III,IV	+0.516	<.001	7	view →
UCEC	All	All	−0.888	<.001	6	view →
HNSC	Male	III,IV	+0.700	<.001	6	view →
BRCA	All	II,III,IV	−0.600	<.001	6	view →
STAD	All	II,III,IV	+0.642	.001	5	view →
CHOL	All	All	+0.934	<.001	3	view →
ESCA	All	All	+0.726	.013	2	view →
PRAD	All	All	−0.588	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

RILPL2–LUAD

Open the LUAD breakdown →